The Albutec GmbH was founded in 2004 by 3 members and now has 5 employees and 2 part-time employees. The company is headquartered in biomedical research center of the Hanseatic city of Rostock. The Albutec GmbH has developed the Hepalbin ® adsorber, through the undesirable stabilizers of the drug for human albumin can be easily removed, resulting in a significant increase in the albumin-binding capacity resulted. The nano-structured Hepalbin adsorbers can be used directly during the infusion or in the preparation of Albumindialysen. The new CE-certified medical Albutec GmbH makes possible for the world's first companies to albumin doses for liver patients without stabilizers octanoate and N-Acetyltryptophanat makes endogenous detoxification and thus offers unique opportunities for in-patients. The Hepalbin adsorber is thus annually for approximately 1 million patients a new treatment alternative. The Albutec GmbH is certified according to DIN EN ISO 13485:2003 and ISO 9001:2000. In addition, the Albutec GmbH owns the wholesale license for the marketing of medicines in accordance with § 52a paragraph 1 AMG.

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is currently in clinical development.

At Inovio, we are seeking to help patients by improving their quality of life through innovative research. Our vision is to address cancers and chronic infectious diseases with a new generation of safe and effective vaccines for preventive and therapeutic purposes. DNA-based vaccines potentially represent a multi-billion-dollar business opportunity. We believe that Inovio's strong intellectual property and proprietary technology relating to electroporation-based DNA vaccines enables us to play a leadership role in advancing the development and potential commercialization of this important new generation of immunotherapies.